Alessio Gerussi
Alessio Gerussi is an expert in Hepatology at University of Milano-Bicocca (Italy). As of October 2026, ScienceLeadR ranks Alessio Gerussi in the top 1% of experts worldwide for Bile Duct Diseases, Biliary Tract Diseases and Cholangitis. Alessio Gerussi has authored 156 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 2 of them ongoing. SLR score: 599 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2026
Number : 156
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prevalence and outcomes of acute presentations of autoimmune hepatitis: Systematic Review and Meta-Analysis. PMID 42946107 — hepatitis, autoimmune, acute-on-chronic liver failure, phenotype, liver, prevalence, liver failure, acute, hepatitis, liver failure | Clin Gastroenterol Hepatol | 2026 | 0 |
| A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals. PMID 42773620 — cholangitis, liver, haplotypes | Liver Int | 2026 | 0 |
| Steroid-loaded Avidin-Nucleic-Acid-Nano-Assemblies reduce hepatic fibrosis modulating Kupffer cells in primary biliary cholangitis. PMID 42486017 — cells, cholangitis, avidin, kupffer cells, fibrosis, pharmaceutical preparations, macrophages, drug therapy, liver, nucleic acids, research, therapeutics, steroids | Biomed Pharmacother | 2026 | 1 |
| Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database. PMID 42488499 — cholangitis, pharmaceutical preparations, therapeutics, health services | Glob Reg Health Technol Assess | 2026 | 0 |
| Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus. PMID 42132745 — liver diseases, hepatitis, autoimmune, insemination, artificial, homologous, cholangitis, liver, diagnosis, therapeutics, immunosuppression therapy, hepatitis | Hepatology | 2026 | 2 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Development of a Autoimmune Hepatitis Patient s Database Linked to a Biological Sample Storage NCT06078098 — hepatitis, autoimmune, insemination, artificial, homologous, epidemiology, laboratories, liver, hepatitis a, hepatitis, prospective studies | N/A | Recruiting | 2023 |
| Vancomycin in Primary Sclerosing Cholangitis in Italy NCT05876182 — liver diseases, bile, cholangitis, bile ducts, intrahepatic, pharmaceutical preparations, bile ducts, drugs, investigational, liver, vancomycin, inflammatory bowel diseases, cholangitis, sclerosing, diagnosis, bile duct diseases, random allocation | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map